Pfizer and BioNTech have launched a clinical trial of a vaccine designed to target the Omicron COVID-19 variant.
In an announcement on Tuesday, the companies said the study will test the safety, tolerability and efficacy of an Omicron-targeting vaccine in more than 1,400 healthy participants from the ages of 18 to 55.
Another vaccine maker, Moderna, has said it hopes to share clinical data on its Omicron-specific vaccine with regulators by March.
Current COVID-19 vaccines were not designed to combat the heavily-mutated Omicron variant - meaning they are not a perfect match.
However, booster doses of the vaccines have been shown to provide good protection against severe illness.
All feeds
